Real-World Safety and Efficacy of the Endeavor Zotarolimus-Eluting Stent: Early Data From the E-Five Registry

American Journal of Cardiology

Volumn 100, Issue 8 SUPPL. 2, 2007, Pages

  Jain, Ajay K ^a   Meredith, Ian T ^b   Lotan, Chaim ^c   Rothman, Martin T ^a   Pateraki, Sofia ^d  

^a BARTS HEALTH NHS TRUST   (United Kingdom)

^b MONASH UNIVERSITY   (Australia)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d Medtronic Bakken Research Centre   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

RAPAMYCIN; UNCLASSIFIED DRUG; ZOTAROLIMUS;

ARTERY DIAMETER; ARTICLE; ASIA; AUSTRALIA; CLINICAL FEATURE; CORONARY ARTERY OBSTRUCTION; DRUG ELUTING STENT; EUROPE; FOLLOW UP; HUMAN; IMPLANTATION; MATERIALS MANAGEMENT; NEW ZEALAND; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; SAFETY; SOUTH AMERICA; SURGICAL TECHNIQUE; SYMPTOM; ZOTAROLIMUS ELUTING STENT;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTI-BACTERIAL AGENTS; CORONARY ARTERY BYPASS; CORONARY DISEASE; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REGISTRIES; SIROLIMUS; TREATMENT OUTCOME;

EID: 35348926980     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.08.026     Document Type: Article

References (7)

1. Kastrati A., Mehilli J., Pache J., Kaiser C., Valgimigli M., Kelbaek H., Menichelli M., Sabate M., Suttorp M.J., Baumgart D., et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 1030-1039
2. Stone G.W., Moses J.W., Ellis S.G., Schofer J., Dawkins K.D., Morice M.C., Colombo A., Schampaert E., Grube E., Kirtane A.J., et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356 (2007) 998-1008
3. Fajadet J., Wijns W., Laarman G.J., Kuck K.H., Ormiston J., Munzel T., Popma J.J., Fitzgerald P.J., Bonan R., and Kuntz R.E. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation 114 (2006) 798-806
4. Kandzari D.E., and Leon M.B. Overview of pharmacology and clinical trials program with the zotarolimus-eluting endeavor stent. J Interv Cardiol 19 (2006) 405-413
5. Meredith I.T., Ormiston J., Whitbourn R., Kay P., Muller D., Bonan R., Popma J.J., Cutlip D.E., Fitzgerald P., Prpic R., and Kuntz R.E. First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in de novo native coronary lesions: Endeavor I Trial. EuroIntervention 1 (2005) 157-164
6. Schultheiss H.P., Grube E., Kuck K.H., Suttorp M.J., Heuer H., Bonnier H., Popma J.J., Kuntz R.E., Fadajet J., and Wijns W. Safety of direct stenting with the Endeavor stent: results of the Endeavor II continued access registry. EuroIntervention 3 (2007) 76-81
7. Kandzari D.E., Leon M.B., Popma J.J., Fitzgerald P.J., O'Shaughnessy C., Ball M.W., Turco M., Applegate R.J., Gurbel P.A., Midei M.G., et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol 48 (2006) 2440-2447